Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congressional collaboration on DTC device ads

This article was originally published in The Gray Sheet

Executive Summary

Sen. Herb Kohl, D-Wis., wants to work with Rep. Bart Stupak, D-Mich., on addressing direct-to-consumer medical device advertisements, "to determine if moratoriums or other proposed restrictions" might be necessary for ads for restricted devices, the Senator writes in a Sept. 26 letter to Stupak, who is chairman of the House Energy and Commerce Committee's oversight sub-panel. Kohl notes that Stupak and Rep. John Dingell, D-Mich., chairman of the House Energy Committee, have asked drug firms to consider a two-year moratorium on DTC ads for new prescription drugs, as recommended by the Institute of Medicine. Kohl held a hearing Sept. 17 on DTC ads for devices ("1The Gray Sheet" Sept. 22, 2008, p. 3)
Advertisement

Related Content

Senate Explores Restrictions On Direct-To-Consumer Device Ads
Senate Explores Restrictions On Direct-To-Consumer Device Ads
Advertisement
UsernamePublicRestriction

Register

MT026638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel